[
  {
    "ts": null,
    "headline": "Behind the Curtain: How UnitedHealth is Rewriting its Own Rules",
    "summary": "UNH is reshaping its model with tech-driven, integrated care as Optum's growth and rising revenues redefine its strategy.",
    "url": "https://finnhub.io/api/news?id=d9e9899919fc6e23d0900737447f854f348513367cdf1f285b24fdad7d4bcaac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765382520,
      "headline": "Behind the Curtain: How UnitedHealth is Rewriting its Own Rules",
      "id": 137750006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "UNH is reshaping its model with tech-driven, integrated care as Optum's growth and rising revenues redefine its strategy.",
      "url": "https://finnhub.io/api/news?id=d9e9899919fc6e23d0900737447f854f348513367cdf1f285b24fdad7d4bcaac"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Outlook For Elevance Health, Inc. (ELV) Supported By Prior TD Cowen Upgrade",
    "summary": "Elevance Health, Inc. (NYSE:ELV) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Elevance Health, Inc. (NYSE:ELV) has a ‘Buy’ or equivalent rating from slightly more than half of the analysts covering the stock. With a median price target of $394, the stock has an upside potential of 19.12%. […]",
    "url": "https://finnhub.io/api/news?id=1eba1e8d4a96ec8abf8d86e065875c1507f4d544f448aa47dcc38c56d93f3115",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765380790,
      "headline": "Wall Street Outlook For Elevance Health, Inc. (ELV) Supported By Prior TD Cowen Upgrade",
      "id": 137750513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Elevance Health, Inc. (NYSE:ELV) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Elevance Health, Inc. (NYSE:ELV) has a ‘Buy’ or equivalent rating from slightly more than half of the analysts covering the stock. With a median price target of $394, the stock has an upside potential of 19.12%. […]",
      "url": "https://finnhub.io/api/news?id=1eba1e8d4a96ec8abf8d86e065875c1507f4d544f448aa47dcc38c56d93f3115"
    }
  }
]